Table 2.
Genetic polymorphism distribution and allele frequencies in clopidogrel-resistant and non-clopidogrel-resistant groups.
| Author | Population | Population Sample | Gene | SNP | Genotype | Allele Frequencies | Total (n/%) |
p-Value | |
|---|---|---|---|---|---|---|---|---|---|
| CR Group (n/%) |
NCR Group (n/%) |
||||||||
| Li et al., 2020 [62] | China | 126 | CYP2C19*2 | rs4244285 | GG (*1/*1) GT (*1/*2) TT (*2/*2) |
9 (23.1%) 21 (53.8%) 9 (23.1%) |
48 (55.2%) 30 (34.5%) 9 (10.3%) |
57 (45.2%) 51 (40.5%) 18 (14.3%) |
0.001 0.041 0.093 |
| CYP2C19*3 | rs4986893 | GG (*1/*1) GT (*1/*3) TT (*3/*3) |
27 (69.2%) 10 (25.6%) 2 (5.1%) |
75 (86.2%) 11 (12.6%) 1 (1.2%) |
102 (80.9%) 21 (16.7%) 3 (2.4%) |
0.025 0.070 0.176 |
|||
| Al-Azzam et al., 2013 [63] | Jordan | 240 | CYP2C19*2 | rs4244285 | GG (*1/*1) GT (*1/*2) TT (*2/*2) |
22 (22.9%) 38 (31.7%) 16 (67.7%) |
74 (77.1%) 82 (68.3%) 8 (33.3%) |
96(40%) 120(50%) 24(10%) |
<0.001 |
| Lee et al., 2009 [64] | Korean | 387 | CYP2C19*2 | rs4244285 | GG GA AA |
55(49.1%) 40(35.7%) 13(11.6%) |
155(56.4%) 93(33.8%) 26(9.5%) |
210(54.3%) 133(34.4%) 39(10.1%) |
0.287 |
| CYP2C19*3 | rs4986893 | GG GA AA |
80(71.4%) 31(27.7%) 1(0.9%) |
236(85.8%) 37(13.5%) 1(0.4%) |
316(81.7%) 68(17.6%) 2(0.5%) |
0.001 | |||
| Amin et al., 2017 [23] | Malaysia | 71 | CYP2C19*2 | rs4244285 | GG (*1/*1) GT (*1/*2) TT (*2/*2) |
11 (40.7%) 8 (29.6%) 8 (29.6%) |
19 (43.2%) 22 (50.0%) 3 (6.8%) |
30 (42.3%) 30 (42.3%) 11(15.5) |
0.026 |
| Alhazzani, et al., 2017 [65] | Saudi Arabia | 50 | CYP2C19*2 | rs4244285 | GG GA + AA |
21(84%) 4(16%) |
10(40%) 15(60%) |
31(62%) 19((38%) |
0.001 |
| CYP2C19*3 | rs4986893 | GG GA + AA |
20(80%) 5(20%) |
13(52%) 12((48%) |
33(66%) 17(34%) |
0.036 | |||
| Shijun et al., 2014 [66] | China | 95 | CYP3A4*G1 | rs2242480 | (GG) (GA + AA) |
24 (61.50%) 15 (38.50%) |
33 (58.90%) 23 (41.10%) |
57 (60.00%) 38 (40.00) |
0.798 |
| Namazi, et al. 2012 [20] | Iran | 112 | CYP3A5 | rs776746 | (*1/*1) (*1/*3) (*3/*3) |
- | - | 9 (8.00%) 42 (37.50%) 61(54.50%) | >0.05 |
| Al-Husein et al., 2018 [67] | Jordan | 280 | CYP3A4 | rs2242480 | (*1/*1) (*1/*3+ *3/*3) |
80(28.6%) 1 (0.4%) |
196 (70%) 3 (1.1%) |
276 (98.6%) 4 (1.4%) |
>0.9999 |
| CYP3A5 | rs776746 | (*1/*1) (*1/*3) (*3/*3) |
57 (20.4%) 23(8.2%) 119(42.5%) |
24(8.6%) 10(3.6%) 47(16.8%) |
81(28.9%) 33(11.8%) 166(59.3%) |
0.961 | |||
| Lee et al., 2009 [64] | Korean | 387 | CYP3A4 | rs2246709 | TT TC CC |
42(37.5%) 57(50.9%) 12(10.7%) |
103(37.5%) 139(50.5%) 28(10.2%) |
145(37.5%) 196(50.6%) 40(10.3%) |
0.925 |
| rs2242480 | GG GA AA |
74(66.1%) 32(28.6%) 6(5.4%) |
172(62.5%) 90(32.7%) 13(4.7%) |
246(63.6%) 122(31.5%) 19(4.9%) |
0.568 | ||||
| CYP3A5 | rs776746 | GG GA AA |
61(54.5%) 41(36.6%) 6(5.4%) |
154(56.0%) 102(37.1%) 12(4.4%) |
215(55.6%) 143(37.0%) 18(4.7%) |
0.808 | |||
| Shasha et al., 2020 [68] | China | 741 | ABCB1 | rs1045642 | GG GA + AA |
94(38.5%) 222(70.3%) |
161(44.4%) 264(62.1%) |
255(34.4%) 486(65.6%) |
0.021 |
| Chen et al., 2021 [69] | China | 204 | MDR1 | rs 1128503 | CC CT TT |
12 (24%) 17 (34.7%) 20 (40.8%) |
40 (25.8%) 65 (41.9%) 50 (32.3%) |
52 (25.5%) 82 (40.2%) 70 (34.3%) |
0.521 |
| Li et al., 2020 [62] | China | 126 | P2Y12 | rs6809699 | GG GT TT |
15 (38.5%) 21 (53.8%) 3 (7.7%) |
67 (79.3%) 18 (20.7%) 2 (2.3%) |
82 (66.7%) 39 (30.9%) 5 (2.4%) |
0.000 0.000 0.152 |
| Namazi et al., 2012 [20] | Iran | 112 | rs2046934 | CC CT + TT |
- | - | 104(92.9%) 8 (7.1%) |
>0.05 | |
| Lee et al., 2009 [64] | Korean | 387 | rs2046934 | TT TC CC |
81(72.3%) 26(23.2%) 4(3.6%) |
177(64.4%) 89(32.4%) 8(2.9%) |
258(66.7%) 115(29.7%) 12(3.1%) |
0.139 | |
CR, clopidogrel resistance; NCR, non-clopidogrel resistance; GG, CC, AA, TT, *1/*1, *2/*2, *3/*3, homozygous; GC, GA, GT, CT, *1/*2, *1/*3, heterozygous.